Correlation between blood magnesium and calcium concentration in patients treated with an anti-EGFR antibody

Tsujii, Toshiyasu; Ogaki, Takafumi; Nakae, Kaori; Imai, K.; Kise, Daisuke; Tada, Shoji; Ueda, Hiroki; Moriyama, Masahiro

doi:10.1186/s40780-016-0060-9

Cited by 6 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18) Tsujii et al have reported that in patients with colon cancer treated with Cmab or panitumumab therapy, serum magnesium levels positively correlated with calcium levels, and our findings are consistent with this previous study. 19) Thus, these electrolytes are assumed to affect each other, and the incidences of electrolyte abnormalities may increase when these correlations are disordered.…”

Section: Discussionmentioning

confidence: 99%

Relationship Between Serum Potassium, Magnesium, and Calcium in Patients Receiving Cetuximab Therapy

Hirata

Ota

et al. 2021

BPB Reports

View full text Add to dashboard Cite

We identified patients with unresectable advanced or recurrent colorectal cancer and head and neck cancer, treated with Cmab from September 2012 to September 2020 using medical records. We excluded patients with a history of anticancer drug therapy. Patients were administered 4 regimens: Cmab monotherapy; SOX+Cmab therapy, which included S-1, oxaliplatin, and Cmab; CBDCA+5-FU+Cmab, which included carboplatin, 5-fluorouracil, and Cmab; PCE therapy, which included paclitaxel, carboplatin,

show abstract

Section: Discussionmentioning

confidence: 99%

Relationship Between Serum Potassium, Magnesium, and Calcium in Patients Receiving Cetuximab Therapy

Hirata

Ota

et al. 2021

BPB Reports

View full text Add to dashboard Cite

show abstract

“…One of the studies reported significant correlation in cancer patients on chemotherapy developing blood magnesium changes (r 2 = 0.7455) [21]. The treatment of hypokalemia is largely dependent on the correction of hypomagnesaemia, if both are occurring simultaneously in a patient.…”

Section: Discussionmentioning

confidence: 99%

Outcomes Related to Electrolyte Imbalance in Patients Undergoing Chemotherapy; an Observational Study Focusing on Cancer Patients

Munir¹,

Ali²,

Kumari³

et al. 2019

CSROA

View full text Add to dashboard Cite

Objectives: Multiple studies are conducted to establish the frequency of electrolyte imbalance outside Pakistan but there is little data available locally. This study was therefore intended to assess the electrolyte imbalance in cancer patients undergoing chemotherapy which can help to reduce the morbidity related to electrolyte imbalance by replacing them appropriately.Methodology: An observational study using non-probability convenient sampling technique was conducted for a year from April 2016 to March 2017 at the Oncology Department of Jinnah Post graduate Medical Center, Karachi after taking the ethical approval from the hospital's Ethical Review Committee. An informed consent was taken from a total of 256 cases diagnosed with various cancers and on an ongoing chemotherapeutic regimen before including them in the study. Age, height, weight, gender, body surface area, type of cancer, chemotherapy protocol, number of days on chemotherapy, electrolyte levels before and after therapy were the variables included. Data was analyzed using the SPSS 20 version. Descriptive statistics of demographic variables was presented as mean, standard deviation and frequency in percentages.Results: 256 patients were included in the study. The mean age of patients was 43.21±12.85 years. 52.7% of the patients showed a reduction in the level of sodium after treatment, followed by 52.2% of the patients showing a reduction in the level of potassium after treatment. 14.8% of the patients presented with reduced chloride levels, with 84.4% of the patients maintaining normal chloride levels before and after treatment. Furthermore, 87.1% of the patients, maintained normal magnesium levels, with 2.7% of the patients presenting with increased magnesium levels after therapy. Conclusion:Our study predicted the significant reduction in the sodium and potassium levels in cancer patients on chemotherapeutic agents. However most of the patients maintained the normal levels of chloride and magnesium.

show abstract

“…In the kidney, magnesium de ciency inhibits the renal outer medullary potassium channel and may cause hypokalemia [13]. Low intracellular magnesium causes hypocalcemia because of being impaired parathyroid hormone secretion [14,15].…”

Section: Introductionmentioning

confidence: 99%

Retrospective Investigation of Factors Influencing Time-dependent Changes in Serum Magnesium Levels in Patients Receiving Cetuximab

Hirata

Ota

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Cetuximab causes electrolyte abnormalities, such as hypomagnesemia, hypokalemia, and hypocalcemia. However, little is known about the relationships between the onset of hypomagnesemia, patient background before administration, and time-dependent changes in serum magnesium levels. Therefore, we examined the patient backgrounds that influenced the onset of hypomagnesemia and the time-dependent changes in serum magnesium levels in patients receiving cetuximab. Methods: A retrospective study was performed to investigate patients with advanced or recurrent colorectal cancer or head and neck cancer, treated with a cetuximab regimen from 2012 to 2020 at Kindai University Nara Hospital. In total, 52 patients who met the inclusion criteria were enrolled in this study. Results: The serum magnesium levels tended to decline with an increasing number of cetuximab administrations. After two administrations of cetuximab, the serum magnesium level was significantly lower in the hypomagnesemia group than in the non-hypomagnesemia group (p < 0.001). The multivariate logistic regression analysis revealed that the baseline serum sodium levels (odds ratio: 0.729, 95% confidence interval: 0.552–0.963) and the combination of magnesium oxide tablet (odds ratio: 0.997, 95% confidence interval: 0.995–0.999) were one of the independent factors for hypomagnesemia. These results indicated that the two administrations of cetuximab may cause magnesium deficiency even if the serum levels are within the normal range. Additionally, hyponatremia before administration may be an indicator of serum magnesium levels after administration of cetuximab.Conclusion: Cetuximab-induced hypomagnesemia may be predicted using baseline serum sodium levels, and hypomagnesemia may be prevented by administration of magnesium oxide tablets. Our findings provided new evidence for the management of serum magnesium levels in patients receiving cetuximab.

show abstract

Correlation between blood magnesium and calcium concentration in patients treated with an anti-EGFR antibody

Cited by 6 publications

References 9 publications

Relationship Between Serum Potassium, Magnesium, and Calcium in Patients Receiving Cetuximab Therapy

Relationship Between Serum Potassium, Magnesium, and Calcium in Patients Receiving Cetuximab Therapy

Outcomes Related to Electrolyte Imbalance in Patients Undergoing Chemotherapy; an Observational Study Focusing on Cancer Patients

Retrospective Investigation of Factors Influencing Time-dependent Changes in Serum Magnesium Levels in Patients Receiving Cetuximab

Contact Info

Product

Resources

About